



Wednesday December 4, 2024

Registration: 1:00 to 1:50 PM

2:00 PM Welcome introduction: Bart Staels, Amalia Gastaldelli

Session 1 – Invited Lectures: The Liver as Central Organ Chairs – François Pattou, John Petrie

- Is diabetes a complication or a driver of MASLD? *Cyrielle Caussy* (Lyon, France)
- Cardiovascular complications. *Christopher Byrne* (Southampton – UK)

3:10 PM Session 2 - Abstracts+oral Posters - MASLD and complications - Chairs: Chris Byrne, Luca Valenti

- Incremental Value of Blood-Based Markers of Liver Fibrosis in Cardiovascular Risk Stratification - *Stavros Athanasopoulos*
- Impact of bariatric surgery on major adverse hepatic and extra-hepatic clinical outcomes in patients with MASLD. - *Weronika Stupalkowska*
- Liver microRNA transcriptome reveals miR-182-5p as link between type 2 diabetes and fatty liver disease in obesity - *Sonja C. Schriever*
- Oral Poster Relationship between Meteorin-like protein and liver disease is associated with metabolic dysfunction in subjects with different glycemic tolerance - *Mariangela Rubino*
- Oral Poster Characterization of transcription factors induced upon hepatocyte reprogramming in liver injury - *Ludivine Vasseur*
- Oral Poster When the liver is in poor condition, so is the heart - cardiac remodelling in MASH mouse models - *Sebastian Bott*

4:00 PM *Coffee break, oral Posters session and networking*

4:30 PM Session 3 - Chairs: Bart Staels, Amalia Gastaldelli (Hybrid session)

Abstracts - New pharmacological strategies for MASH

- Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis - *Cyrielle Caussy*
- Pharmacological inhibition of fructose metabolism reduces liver fat and improves insulin sensitivity in participants with MASLD - *Evi J.C. Koene*
- Beyond GLP-1, managing cirrhosis and complications in patients with advanced MASH - *Phil Ambery*
- Comparative effect estimates of tirzepatide, semaglutide and liraglutide in risk reduction of major adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease - *Alex Henney*

Invited Lectures: MASLD Guidelines and Non-invasive Tests

- Update on new EASL-EASD-EASO guidelines for MASLD. *Sven Francque* (UZA, Antwerp, Belgium) 25 min
- Non-invasive tests for MASLD screening. *Laurent Castera* (Paris, France) 25 min
- *Round table with panel discussion*



Thursday December 5, 2024

9:00 AM Session 4 - Invited Lectures: Tic toc: how insulin resistance changes the metabolic clock - Chairs: John Petrie, Nebosja Lalic

- Circadian clock in MASLD. *Hélène Duez* (UMR 1011, Lille, France)
- Time restricted feeding in metabolism. *Paola Tognini* (Pisa, Italy)
- The brain is central. *Vincent Prevot* (Univ. Lille, France)

10:30 AM Session 5 Abstracts+oral Posters - Immunity bacteria and MASLD Chairs: Hélène Duez, Olivier Govarae

- Specific immune response prevents the development of fibrosis in fatty liver of mice with glycogen storage disease type Ia *Gwendoline Perrot*
- Next-generation beneficial bacteria combined with fructo-oligosaccharides and fecal microbiota transplantation attenuates diet-induced metabolic dysfunction-associated steatosis in mice *Ting Chen*
- The trained immunity response is suppressed in individuals with metabolic dysfunction-associated steatotic liver disease - *Helen Roche*
- The ubiquitin-like modifier FAT10 regulates the senescence of hepatocytes during Metabolic dysfunction-Associated Steatohepatitis progression - *Rejane Lestrelin*
- Oral Poster HSD17B13 drives the antisteatotic effect of a novel thyroid hormone receptor beta agonist - *Andrea Marco Caddeo*
- Oral Poster Rewire of liver transcriptome and metabolome in response to high-fat diet or weight loss in a mouse model of obesity - *Silvia Sabatini*

11:30 AM *Coffee break, oral Posters session and networking*

12:00 PM Session 6 Abstracts+oral Posters - The liver and beyond - Chairs: Caroline Bonner, Delphine Eberlé

- Fetuin-A, a novel player in the modulation of alpha-cell function. - *Mariangela Rubino*
- Major effects of Dapagliflozin treatment on amino acid metabolism in patients with diabetes - *Samantha Pezzica*
- Deciphering a Novel Mechanisms of Insulin Resistance: Circular Dorsal Ruffles and Insulin Receptor Trafficking in Hepatocytes - *Akiko Teshima*
- From the liver to the muscle: The compensatory mechanism of extracellular Vesicles in prediabetes - *Pedro Ribeiro*
- Oral Poster Efficacy of Dodecanedioic acid Treatment for MAFLD Prevention and Reversal - *Sara Russo*
- Oral Poster Impact of MASLD with advanced fibrosis on post-prandial response glucose and lipid metabolism during a mixed-meal tolerance test in type 2 diabetes (T2D). - *Marion Pradeau*

1:00 PM *Lunch break*



2:00 PM Session 7 - Invited Lectures: Heterogeneity of MASLD - Chairs: Anne-Marie Carreau, Catherine Postic

- Sexual Dimorphism and genetic variants. *Luca Valenti* (Milan, Italy)
- Data-driven cluster analysis identifies distinct types of MASLD. *François Pattou* (CHU Lille, France)

3:00 PM Session 8 Abstracts+oral Posters- Molecular hepatic alterations linked to MASLD Chairs: Isabelle Gonzales Mariscal, Jérôme Eeckhoutte

- Role of FAT10 in Mallory Denk bodies formation during MASH development in hepatocytes - *Arthur Cens*
- O-GlcNAcylation controls pro-fibrotic transcriptional regulatory signaling in hepatic stellate cells - *Ninon Very*
- Role of O-GlcNAc transferase (OGT) in the control of liver physiology - *Eva Level*
- Role of ChREBP in pathophysiology of MASLD : sex-specific traits - *Marion Régnier*
- A New 3d Spheroid Model Of Hepatocyte/Liver Injury - *Sadia Raab*
- Oral Poster Liver sinusoidal endothelial cells affect lipid metabolism in hepatocytes and form lipid droplets under steatotic conditions - *Ting Chen*
- Oral Poster Association between serum Uric Acid levels and MASLD in caucasian patients with T2DM - *Mattia Massimino*
- Oral Poster Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH - *Laurent L'homme*

4:15 PM Coffee break, oral Posters session and networking

4:45 PM Session 9 - (Hybrid session) - Chairs: Patrick Schrauwen, Ulf Riserus

Abstracts - Adipose tissue: Metabolic and Cellular Adaptations in Obesity and Dietary Interventions

- Peripheral insulin sensitivity is lower after 4-week high-fructose compared to 4-week high-saturated fat consumption in overweight individuals - *Kay HM Roumans*
- Obesity and weight loss change differently the metabolomic profile of white and brown adipose tissue - *Lia De Benedictis*
- Metabolic adaptations of resident macrophages in the physiopathological context of MASLD - *Razafiarison Joanna*

Invited Lectures: Adipose Tissue and Lipotoxicity

- Adipose tissue adaptation in obesity. *Michael Ryden* (Stockholm Sweden) 25min
- Adipose tissue-liver cross-talk. *Delphine Eberlé* (Lille, France) 25 min
- Round table with panel discussion

Light Dinner and networking



Friday December 6, 2024

9:00 AM Session 10- Invited Lectures: *Metabolic determinants of hepatocyte function* - Chairs: Paula Macedo, Chiara Saponaro

- Role of the liver in the pathogenesis of fasting hyperglycemia. *Andrea Natali* (Pisa – Italy)
- ERR – PPAR α interactions in hepatic lipid metabolism. *Karolien De Bosscher* (VIB, Ghent University, Belgium)

10:00 AM Session 11 Abstracts+oral Poster - *Metabolic and molecular changes in the liver* Chairs: Mina Mitrakou, Vera Schrauwen

- Circulating long-chain ceramide signatures linked to diabetic MASLD: mechanistic insights and diagnostic implications - *Josep Julve*
- The degree of metabolic dysfunction in MASLD and MetALD, and its interaction with liver fibrosis, differentially affects risk of incident MALO, MACE, obesity-related cancers and increases all-cause mortality. - *Daniel Cuthbertson*
- Unveiling the Protein Cargo of HDL particles in Metabolic Dysfunction-Associated Steatohepatitis: A Biomarker Study - *Fiona McGillicuddy*
- Oral Poster Histological features distinguish alcoholic from metabolic dysfunction-associated steatohepatitis - *Tessa Ostyn*
- Oral Poster Type 2 diabetes (T2D) and obesity differently impact the metabolic profile of subjects with metabolic dysfunction-associated steatohepatitis (MASH) - *Patrizia Infelise*
- Oral Poster Fetuin B is related to cytokine/chemokine and insulin signaling in adipose tissue and plasma in humans - *Ruth Meex*
- Oral Poster Nitrate-mediated dilation is impaired in people with type 1 diabetes and co-existent metabolic dysfunction-associated steatotic liver disease - *Jonathan Mertens*
- Oral Poster The influence of the Endocannabinoid System on islet function in the progression from glucose intolerance to diabetes: Implications for therapeutic intervention - *Elise Wreven*
- Oral Poster Effects of enhanced intracellular hydrogen sulfide production in pancreatic islets: insights into type 2 diabetes - *Inmaculada Pino*
- Oral Poster Impact of COVID-19 on ectopic fat accumulation and postprandial glucose metabolism- *Sandrine Beaulieu*

11:15 AM Session 12 - Invited Lectures: *Molecular determinants of hepatocyte function* Chairs: Joel Haas, Paola Tognini

- Maintenance of Hepatocyte Identity in metabolic disease. *Jérôme Eeckhoutte* (UMR1011 Lille, France)
- Macrophages in the liver. *Oliver Govaere* (Leuven, Belgium)

12:10 PM Award ceremony for the 2 best Abstracts by young researchers

Closing remarks